Target, Home Depot,...
Health Care: Drugs
Pharmacyclics Incorporated (PCYC: NASDAQ)
$84.89 0.97 | 1.16%
05/17/13 - 04:00 PM ET
838.44K / 806.50K
Vol / Avg. Vol:84.37 / 83.92
Open / Prev. Close:83.06 - 85.06
Today's Range:27.30 - 95.85
52 Wk Range:45.24%
Performance YTD:TheStreet Rating:
Portfolios with PCYC
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserGFNN Stockdiagnostics 28
- UserGFNN Stockdiagnostics 20
- ContributorStocks Rising On Unusual Vo...
- ContributorHot Biotech Stocks Traded b...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor10 Best-Performing Stocks i...
- ContributorStocks At New 52-Week Highs...
Latest PCYC Headlines from TheStreet
- ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up 05.15.13 | 06:05 pm
- ASCO '13 Preview: Gilead's Big Cancer Debut 05.15.13 | 06:05 pm
- 10 ASCO '13 Abstracts You Can Read Right Now 05.15.13 | 06:05 pm
- Pharmacyclics Rises On Unusually High Volume (PCYC) 05.13.13 | 03:05 pm
- 3 Biotech Stocks Spiking With Big Volume 05.13.13 | 02:05 pm
- Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Winner 04.22.13 | 05:04 pm
- Pharmacyclics Incorporated (PCYC): Drugs' Featured Daily Laggard 04.09.13 | 05:04 pm
- TheStreet Ratings Top 10 Rating Changes 04.08.13 | 09:04 am
- Pharmacyclics Incorporated Stock Downgraded (PCYC) 04.05.13 | 05:04 am
- Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Laggard 03.19.13 | 05:03 pm
Press Releases for PCYC
- Pharmacyclics Completes Enrollment Of First Phase III Ibrutinib CLL Study - RESONATEâ¿¢ And Announces Completion Of Enrollment Of Phase II Ibrutinib MCL Study - SPARK - PR Newswire 04.18.13 | 04:04 pm
- Pharmacyclics Triggers Fourth Milestone Payment For Enrollment Of 5th Patient In Frontline Phase III CLL Study - PR Newswire 04.11.13 | 06:04 am
- Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid And Sustainable Disease Control Irrespective Of Age Or High Risk Prognostic Factor - PR Newswire 04.08.13 | 01:04 pm
- Pharmacyclics Announces Third Breakthrough Therapy Designation For Ibrutinib From The U.S. Food And Drug Administration - PR Newswire 04.08.13 | 06:04 am
- Pharmacyclics, Inc. Prices Public Offering Of Common Stock - PR Newswire 03.08.13 | 08:03 am
- Pharmacyclics, Inc. Announces Proposed Public Offering Of Common Stock - PR Newswire 03.07.13 | 04:03 pm
- Pharmacyclics First To Announce Breakthrough Therapy Designation In Oncology From The U.S. Food And Drug Administration - PR Newswire 02.12.13 | 07:02 pm
- Pharmacyclics Announces Date Of Financial Results For Three And Six Months Ended December 31, 2012 And Conference Call - PR Newswire 02.07.13 | 04:02 pm
- Pharmacyclics® Announces Updated Results For BTK Inhibitor Ibrutinib (PCI-32765) At American Society Of Hematology (ASH) Annual Meeting - PR Newswire 12.11.12 | 04:12 pm
- Follow-up Results Of Phase 2 Study Of Investigational Agent, Ibrutinib, Suggest High And Durable Responses In Relapsed/Refractory Mantle Cell Lymphoma - PR Newswire 12.11.12 | 07:12 am
Partner Headlines for PCYC
- Short Interest in Vertex Rises, in Celgene Falls - Benzinga 05.11.13 | 10:05 am
- Amgen, Inc. (AMGN): Today's Most Compelling Stock Buy - NASDAQ 05.09.13 | 04:05 pm
- Pharmacyclics Inc. (PCYC): Today's Most Compelling Stock Buy - NASDAQ 05.07.13 | 05:05 pm
- Polycyclics Inc. (PCYC): Today's Most Compelling Stock Pick - NASDAQ 04.26.13 | 07:04 pm
- Biotech Stocks Get A Turbo Boost From Vertex - Seeking Alpha 04.20.13 | 09:04 am
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
- Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy - NASDAQ 03.14.13 | 04:03 pm
- Pharmacyclics Is Ripe For A Major Correction - Seeking Alpha 02.16.13 | 06:02 am
- UPDATE: Dawson James Initiates Pharmacyclics at Market Outperform on Ibrutinib Confidence - Benzinga 12.07.12 | 09:12 am
- Celgene, Regeneron Pharmaceutical Lead Biomed Group - Investor's Business Daily 11.30.12 | 05:11 pm
